Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

In a large cohort of patients with HER2-positive early breast cancer (n=396), a dual HER2-targeted combination of pertuzumab and trastuzumab, together with 8 cycles of taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, was well tolerated and achieved high rates of pathological complete response.

from Cancer via ola Kala on Inoreader http://annonc.oxfordjournals.org/cgi/content/short/mdw610v1?rss=1
via IFTTT